Global Water Resources Declares Monthly Dividend
Oct 31, 2016 12:31 pm UTC| Business
PHOENIX, Oct. 31, 2016 -- Global Water Resources, Inc. (NASDAQ:GWRS), (TSX:GWR), a pure-play water resource management company, has declared, under its dividend policy, a monthly cash dividend in the amount of $0.022...
Reed's, Inc. Announces Board of Director Nominees
Oct 31, 2016 12:31 pm UTC| Business
LOS ANGELES, Oct. 31, 2016 -- (NYSE-MKT:REED), maker of the top selling craft sodas nationwide announced today that the Board of Directors has named its slate of Directors for consideration for election at its 2016...
Reed's, Inc. Announces Board of Director Nominees
Oct 31, 2016 12:31 pm UTC| Business
LOS ANGELES, Oct. 31, 2016 -- (NYSE-MKT:REED), maker of the top selling craft sodas nationwide announced today that the Board of Directors has named its slate of Directors for consideration for election at its 2016...
PositiveID’s E-N-G Mobile Systems’ Service Business in Q3 Grew 70% over the First Half of 2016
Oct 31, 2016 12:31 pm UTC| Business
DELRAY BEACH, Fla., Oct. 31, 2016 -- PositiveID Corporation (“PositiveID” or “Company”) (OTCQB:PSID), a life sciences company focused on detection and diagnostics, announced today that the service business at its E-N-G...
PositiveID’s E-N-G Mobile Systems’ Service Business in Q3 Grew 70% over the First Half of 2016
Oct 31, 2016 12:31 pm UTC| Business
DELRAY BEACH, Fla., Oct. 31, 2016 -- PositiveID Corporation (“PositiveID” or “Company”) (OTCQB:PSID), a life sciences company focused on detection and diagnostics, announced today that the service business at its E-N-G...
Oct 31, 2016 12:31 pm UTC| Business
51% of patients in the high responder subset receiving Ampligen vs. 18% of placebo patients demonstrated improvement of at least 25% in exercise tolerance ...
SteadyMed to Present at the 25th Annual Credit Suisse Healthcare Conference
Oct 31, 2016 12:30 pm UTC| Business
SAN RAMON, Calif., Oct. 31, 2016 -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral...